KDR and neoplasm: First, sorafenib blocks tumor cell proliferation by targeting Raf-MEK-ERK pathway and exerts tumor angiogenesis by targeting VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β [9, 10], which is different from the molecular mechanism of hepatocarcinogenesis [20].